Medications for the Treatment of Dysthymic Disorder and Double Depression
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00234312|
Recruitment Status : Unknown
Verified September 2006 by Oregon Health and Science University.
Recruitment status was: Active, not recruiting
First Posted : October 6, 2005
Last Update Posted : September 11, 2006
|Condition or disease||Intervention/treatment||Phase|
|Depression Dysthymia||Drug: escitalopram and sertraline||Phase 4|
Dysthymic Disorder is a common, chronic type of depression that is often seen as a mild condition and is under-treated. Because of its chronic course, it is often complicated by episodes of major depression and may require long-term treatment.
This is a twelve week study during which daily doses of escitalopram (10-20 mg) or sertraline (50-200 mg) will be given to outpatients meeting criteria for Dysthymic Disorder or Double Depression. Medications will be assigned 1:1 and clinicians will be blinded to treatment. Efficacy will be based on scores for the Hamilton Depression Rating Scale, patient subjective reporting, and clinician observation. The study will have a total of 8 visits over 12 weeks, with a one-week medication taper period at the end. Subjects will have a physical exam, labs, and vital signs monitored at first visit and vital signs monitored at every subsequent visit. Women of childbearing potential must have a negative urine pregnancy test at screening. All subjects will remain on the lowest medication dose for the first four weeks of the study.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||Escitalopram Vs. Sertraline in the Treatment of Dysthymic Disorder and Double Depression|
|Study Start Date :||September 2005|
|Study Completion Date :||October 2006|
- score on first 17 items of HAM-D Rating Scale 24 item, each visit
- scores on HAM-D 21, HAM-D 24, and Beck Depression Inventory (pt. rated)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00234312
|United States, Oregon|
|Oregon Health Sciences University|
|Portland, Oregon, United States, 97239|
|Principal Investigator:||Joshua Boverman, MD||Oregon Health and Science University|